NeuroMetrix Celebrates 10,000 Quell Facebook Fans with Pain Awareness Month Contest
NeuroMetrix, Inc. (NASDAQ:NURO) announced today that to celebrate having reached 10,000 fans for Quell® Pain
Relief on Facebook, it will give away a contest prize each day during September which is Pain Awareness Month. Consumers are
encouraged to follow the Quell Facebook page for details on how to enter the contest.
“The rapid growth of the Quell Facebook community is an indicator of the growing awareness and enthusiasm for our Quell Wearable
Pain Relief Technology™ among consumers,” says Frank McGillin, NeuroMetrix Senior Vice President and General Manager,
Consumer. “We value the opportunity to engage with existing and prospective Quell users and have been moved by the stories about
how Quell is fundamentally impacting the quality of people’s lives.”
The Quell Pain Relief Facebook community has given Quell an average 4.6 star rating. Some recent reviewers have written:
- “Thank you so much for making this miracle pain relief device.” – Linda F.
- “I do love this thing!!!! I have gone from taking pain medication every 3 hours to just taking
morning and evening. What a life changer.” – Debra R.
- “Thank you Quell for making me so happy with my life again!!!!!” – Kim M.
- “It really does work!!! I am certainly enjoying my pain free lifestyle, thank you Quell!!! I've got
my life back!!!” – Doug P.
About Quell Wearable Pain Relief Technology
Quell is an easy-to-use, over-the-counter device for relief of chronic pain. This wearable device
utilizes NeuroMetrix's patented technology to provide widespread pain relief. In a recent clinical study, Quell improved
chronic pain in 81% of participants. Quell is currently available through select healthcare professionals, retailers, and online
at www.QuellRelief.com.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep disorders and diabetes. The company’s lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets
DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for
restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from
the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Neurometrix.ir@neurometrix.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160822005776/en/